Journal of Oral and Maxillofacial Surgery
Volume 65, Issue 12 , Pages 2397-2410 , December 2007

Oral Bisphosphonate-Induced Osteonecrosis: Risk Factors, Prediction of Risk Using Serum CTX Testing, Prevention, and Treatment

  • Robert E. Marx, DDS

      Affiliations

    • Professor of Surgery and Chief, Division of Oral and Maxillofacial Surgery, University of Miami Miller School of Medicine, Miami, FL.
    • Corresponding Author InformationAddress correspondence and reprint requests to Dr Marx: Division of Oral and Maxillofacial Surgery, University of Miami Miller School of Medicine, 9380 SW 150th St, Suite 190, Miami, FL 33157
    • ,
  • Joseph E. Cillo Jr, DDS

      Affiliations

    • Attending Surgeon, Oral and Maxillofacial Surgery, Alleghany General Hospital, Pittsburgh, PA.
    • ,
  • Juan J. Ulloa, DDS

      Affiliations

    • Fellow in Tumor and Reconstructive Surgery, Division of Oral and Maxillofacial Surgery, University of Miami Miller School of Medicine, Miami, FL.

References 

  1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg. 2003;61:1115
  2. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg. 2005;63:1567
  3. Ruggerio SL, Mekrota B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg. 2004;62:527
  4. Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Med J Aust. 2005;182:417
  5. Migliorati CA, Schubert MM, Peterson DE, et al. Bisphosphonate associated osteonecrosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy. Cancer. 2005;104:83
  6. Bagan JV, Jimenez Y, Murillo J, et al. Jaw osteonecrosis associated with bisphosphonates multiple exposed areas and its relationship to teeth extractions (Study of 20 cases). Oral Oncol. 2006;42:327
  7. Brooks JK, Gilson AJ, Sindler AJ, et al. Osteonecrosis of the jaws associated with use of residronate (Report of 2 new cases). Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103:780
  8. Mavrokoski T, Cheng A, Stein B, et al. Nature and frequency of bisphosphonate associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007;65:415
  9. Wynn RL. Oral bisphosphonates and osteonecrosis of the jaw. Gen Dent. 2007;55:8
  10. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the JawsAmerican Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369
  11. Varney LF, Parker RA, Vincelette A, et al. Classification of osteoporosis and osteopenia in postmenopausal women in dependent on site-specific analysis. J Clin Densitom. 1999;2:275
  12. Leib ES, Lewiecki EM, Binkley N, et al. Official positions of the International Society for Clinical Densitometry. J Clin Densitom. 2007;7:1
  13. Neff MJ. Practical guidelines: ACOG releases guidelines for clinical management of osteoporosis. Am Fam Physician. 2004;69:1
  14. Licata AA. Discovery, clinical development, and therapeutic uses of bisphosphonate. Ann Pharmacother. 2005;39:668
  15. Product information (Fosamax). Whitehouse Station, NJ: Merck Co; 2005;
  16. Product information (Actonel). Cincinnati, OH: Procter and Gamble Pharmaceuticals; 2005;
  17. Lasseter KC, Porras AG, Denker A, et al. Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates. Clin Drug Invest. 2005;25:107
  18. Product information sheet, Aredia (Pamidronatate sodium for injection, for intravenous infusion). East Hanover, NJ: Novartis AG; 2001;
  19. Zometa (Zoledronic acid injection product information sheet). East Hanover, NJ: Novartis AG; 2004;
  20. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88:2961
  21. Adoina CV, Zerwekh JE, Rao S, et al. Severely suppressed bone turnover: A potential complication of Alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294
  22. Dixon RB, Tricker ND, Garetto LP. Bone turnover in elderly canine mandibles and tibia. (IADR Abstracts) J Dent Res. 1997;76:2579
  23. Viznery A, Baron R. Dynamic histomorphometry of alveolar bone remodeling in the adult rat. Anat Rec. 1980;196:191
  24. Brunski JB. In vivo bone response to biochemical loading at the bone/dental-implant interface. Adv Dent Res. 1999;13:99
  25. In:  Marx RE editors. Risks, prevention, and management of intravenous bisphosphonate-induced osteonecrosis of the jaws. Hanover Park, IL: Quintessence Publ; 2006;p. 77–95History, Etiology, Prevention, and Treatment
  26. Garnero P, Delmas PD. Biochemical markers of bone turnover: Applications for osteoporosis. Endocrinol Metab Clin North Am. 1998;27:303
  27. Rosen HN, Moses AC, Garber J, et al. Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates. Calcif Tissue Int. 1998;63:363
  28. Rosen HN, Moses AC, Garber J, et al. Serum CTX (A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy). Calcif Tissue Int. 2000;66:100
  29. US Food and Drug Administration. FDA publication 04-1322C. 2004;
  30. Black DM, Thompson DE, Bauer DC, et al. Fracture Intervention Trial Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group [Erratum in 86:938, 2001] J Clin Endocrinol Metab. 2000;85:4118
  31. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333:1437
  32. Melton LJ, Khosla S, Achenbach SJ, et al. Effects of body size and skeletal site on the estimated prevalence of osteoporosis in women and men. Osteoporos Int. 2000;11:977
  33. Cummings SR, Karpf DB, Harris F. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112:281
  34. Sarkar S, Mitlak BH, Wong M, et al. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002;17:1
  35. Marcus R, Wong M, Heath H, et al. Antiresorptive treatment of postmenopausal osteoporosis: Comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev. 2002;23:16
  36. Bone HG, Hosking D, Devogelaer JP, et al. Ten years experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189
  37. Black DM, Schwartz AV, Ensrud KE, et al. FLEX Research Group Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial. JAMA. 2006;296:2927
  38. Rinchuse DJ, Rinchuse DJ, Sosovicka MF, et al. Orthodontic treatment of patients using bisphosphonates: A report of 2 cases. Am J Orthod Dentofacial Orthop. 2007;131:321
  39. Zahorski JJ. Bisphosphonate treatment: An orthodontic concern calling for a proactive approach. Am J Orthod Dentofacial Orthop. 2007;131:311
  40. Jeffcoat MK. Safety of oral bisphosphonates: Controlled studies on alveolar bone. Int J Oral Maxillofac Implants. 2006;21:349

PII: S0278-2391(07)01594-7

doi: 10.1016/j.joms.2007.08.003

Journal of Oral and Maxillofacial Surgery
Volume 65, Issue 12 , Pages 2397-2410 , December 2007

Article Tools

* Image Usage & Resolution